SeaCreation Pharmaceuticals: Mid-term analysis results of the HP515 clinical phase IIa trial achieved.

Huaichuang Pharmaceutical announced that the independent research and development of the innovative drug HP515, a type 1 innovation drug, for the treatment of metabolic steatohepatitis has achieved positive interim analysis results in the clinical phase IIa trial. After 12 weeks of treatment in 50 patients, the main efficacy endpoint showed a significant decrease in liver fat content in all groups of HP515 compared to baseline, with statistically significant differences compared to the placebo group. The overall safety and tolerability of HP515 at various doses for 12 weeks of oral administration were good, with no reports of serious adverse events, severe adverse events, or drug-related withdrawals. The majority of adverse events were transient and mild to moderate.